Startup / Venture Capital / Healthtech / Biotech / Diagnostics / RNA Therapeutics / Climate Tech / Critical Materials
Intu Diagnostics, Thalia Therapeutics, RarEarth — lab-free testing, clinical RNA and European rare earths — Daily News June 26, 2026
01:52
•
26/06/2026
Listen on Spotify🇮🇹 Podcast in Italian
About this episode
Intu Diagnostics raises €1.1M to bring molecular diagnostics outside laboratories, Thalia Therapeutics raises €3.1M and acquires Sanmirna to accelerate a clinical-stage RNA pipeline, while RarEarth secures a €2.5M EIC grant to recycle rare earths from electronic waste.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Startups mentioned
Intu Diagnostics
Intu Diagnostics develops a lab-independent molecular diagnostics platform, initially focused on HPV testing in women's health.
Thalia Therapeutics
Thalia Therapeutics raises €3.1M and acquires Sanmirna Therapeutics, adding a clinical-stage microRNA candidate for AML.
RAREARTH S.R.L.
Rare earth magnet recycling company enabling a sustainable circular economy for permanent magnets used in EV motors, wind turbines, and electronics.
Listen to the episode
Listen on Spotify🇮🇹 Podcast in Italian